339 related articles for article (PubMed ID: 34276706)
1. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
Front Immunol; 2021; 12():613502. PubMed ID: 33968017
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
Ranganathan S; Iyer RN
Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
7. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
8. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B; Vanhove B; Vibet MA; Le Thuaut A; Lacombe K; Dubee V; Ader F; Ferre V; Vicaut E; Orain J; Le Bras M; Omnes A; Berly L; Jobert A; Morineau-Le Houssine P; Botturi K; Josien R; Flet L; Degauque N; Brouard S; Duvaux O; Poinas A; Raffi F;
Trials; 2021 Mar; 22(1):199. PubMed ID: 33750432
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
Front Immunol; 2021; 12():633323. PubMed ID: 34790190
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
Franchini M; Del Fante C; Klersy C; Glingani C; Percivalle E; Baldanti F; Perotti C
Semin Thromb Hemost; 2020 Oct; 46(7):804-806. PubMed ID: 32512588
[No Abstract] [Full Text] [Related]
16. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Donato ML; Park S; Baker M; Korngold R; Morawski A; Geng X; Tan M; Ip A; Goldberg S; Rowley S; Chow K; Brown E; Zenreich J; McKiernan P; Buttner K; Ullrich A; Long L; Feinman R; Ricourt A; Kemp M; Vendivil M; Suh H; Balani B; Cicogna C; Sebti R; Al-Khan A; Sperber S; Desai S; Fanning S; Arad D; Go R; Tam E; Rose K; Sadikot S; Siegel D; Gutierrez M; Feldman T; Goy A; Pecora A; Biran N; Leslie L; Gillio A; Timmapuri S; Boonstra M; Singer S; Kaur S; Richards E; Perlin DS
JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33571168
[TBL] [Abstract][Full Text] [Related]
17. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.
Moore JL; Ganapathiraju PV; Kurtz CP; Wainscoat B
Am J Case Rep; 2020 Oct; 21():e927812. PubMed ID: 33009361
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.
Hähnel V; Peterhoff D; Bäuerlein V; Brosig AM; Pamler I; Johnson C; Bica A; Totir M; Ossner T; Stemmer B; Toelge M; Schütz A; Niller HH; Schmidt B; Wagner R; Gessner A; Burkhard R; Offner R
PLoS One; 2020; 15(12):e0243967. PubMed ID: 33351831
[TBL] [Abstract][Full Text] [Related]
19. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
20. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
Focosi D; Franchini M
Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
